Quarterly report · Q2
7446.TEDINET S100TF5Q
Period2023-10-01 → 2024-03-31
Filed2024-05-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.6bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥35.1bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥18.4bn | 2022-10-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥276m | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥532m | 2022-10-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥302m | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥808m | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥552m | 2022-10-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥314m | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥552m | 2022-10-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥211m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥556m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥367m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥213m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥373m | 2022-10-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥19.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥18.9bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥17.8bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥12.1bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥11.7bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥7.6bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥7.0bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.2bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2022-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥226m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥185m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥54m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥335m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥288m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥83m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥96m | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥46m | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥233.86 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥174.52 | 2024-01-01 → 2024-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥617.29 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥407.21 | 2022-10-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥204.9 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 38.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥8.3bn |
| jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥8.3bn |
| jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥7.1bn |
| jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥7.1bn |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥16.6bn |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥16.6bn |
| jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥1.3bn |
| jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥9.1bn |
| jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥9.1bn |
| jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segment | revenue | 2022-10-01 → 2023-03-31 | ¥8.1bn |
| jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segment | revenue external | 2022-10-01 → 2023-03-31 | ¥8.1bn |
| —segment total | revenue | 2022-10-01 → 2023-03-31 | ¥18.4bn |
| —segment total | revenue external | 2022-10-01 → 2023-03-31 | ¥18.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 505
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -79585000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -42803000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -189174000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -108013000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -23030000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -24442000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YTDDuration | 5000000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYTDDuration | 34448000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -139202000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -5000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 139202000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 75000000 | JPY |
| Proceeds from cancellation of insurance funds inv cf | Prior1YTDDuration | － | JPY |
| Proceeds from cancellation of insurance funds inv cf | CurrentYTDDuration | 11083000 | JPY |
| Other net inv cf | Prior1YTDDuration | -1258000 | JPY |
| Other net inv cf | CurrentYTDDuration | 5938000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -288048000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -53790000 | JPY |
| Increase in short term loans payable fin cf | Prior1YTDDuration | 1166000000 | JPY |
| Increase in short term loans payable fin cf | CurrentYTDDuration | 1895000000 | JPY |
| Decrease in short term loans payable fin cf | Prior1YTDDuration | -1083200000 | JPY |
| Decrease in short term loans payable fin cf | CurrentYTDDuration | -1846200000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -7140000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -7140000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -103351000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -94457000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -18782000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -30080000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -46474000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -82878000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -149036000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 89628000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1268452000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2106274000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 1119415000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 2195902000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 707696000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 757049000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | -1738000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 1635000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 57560000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 54410000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 22867000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 21093000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 5727000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 6005000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02810-000IndustrySalesGroupReportableSegmentMember | 9080592000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02810-000MedicalSalesGroupReportableSegmentMember | 8054421000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02810-000AcademiaLifeScienceSalesGroupReportableSegmentMember | 1310845000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 18445860000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |